Ebola

Ebola virus disease, or simply Ebola, is a disease of humans and other primates caused by ebolaviruses.

Post-Ebola virus syndrome (or post-Ebola syndrome) is a post-viral syndrome affecting those who have recovered from infection with Ebola.

BCX4430 (Immucillin-A) is an antiviral drug, an adenosine analog (a type of nucleoside analog).

cAd3-ZEBOV (also known as the NIAID/GSK Ebola vaccine or cAd3-EBO Z) is an experimental vaccine for two ebolaviruses, Ebola virus and Sudan virus, developed by scientists at GlaxoSmithKline (GSK) and tested by National Institute of Allergy and Infectious Disease (NIAID).

FGI-106 is a broad-spectrum antiviral drug developed as a potential treatment for enveloped RNA viruses, in particular viral hemorrhagic fevers from the bunyavirus, flavivirus and filovirus families.

Vesicular Stomatitis Virus-Ebola Virus vaccine — known as VSV-EBOV — is an experimental vaccine for protecting against Ebola virus disease.

JK-05 is a broad-spectrum antiviral drug developed by the Chinese company Sihuan Pharmaceutical along with the Chinese Academy of Military Medical Sciences.

ZMapp is an experimental biopharmaceutical drug comprising three chimeric monoclonal antibodies under development as a treatment for Ebola virus disease.

FGI-103 is an antiviral drug developed as a potential treatment for the filoviruses Ebola virus and Marburg virus.

FGI-104 is the name for a family of chemical compounds that act as broad-spectrum antiviral drugs, with activity against a range of viruses including Hepatitis B, Hepatitis C, HIV, Ebola virus and Venezuelan equine encephalitis virus.

Brincidofovir (CMX001) is an experimental antiviral drug being developed by Chimerix of Durham, NC, for the treatment of cytomegalovirus, adenovirus, smallpox, and ebolavirus infections.

Favipiravir, also known as T-705 or Avigan, is an experimental antiviral drug being developed by Toyama Chemical of Japan with activity against many RNA viruses.